Vivarelli M, Bomback AS, Meier M, et al. Iptacopan in idiopathic immune complex–mediated membranoproliferative glomerulonephritis: protocol of the APPARENT multicenter, randomized phase 3 study. Kidney Int Rep. 2024;9(1):64–72.

Article  PubMed  Google Scholar 

Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;81(5):434–41.

Article  PubMed  Google Scholar 

Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015;11(1):14–22.

Article  CAS  PubMed  Google Scholar 

Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant. 2023;38(2):283–90.

Article  CAS  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–276.

Google Scholar 

Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant. 2012;27(12):4288–94.

Article  CAS  PubMed  Google Scholar 

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis—a new look at an old entity. N Engl J Med. 2012;366(12):1119–31.

Article  CAS  PubMed  Google Scholar 

Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–64.

Article  CAS  PubMed  Google Scholar 

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011;31(4):341–8.

Article  CAS  PubMed  Google Scholar 

Meuleman MS, Roquigny J, Brousse R, et al. Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN. Nephrol Dial Transplant. 2024. https://doi.org/10.1093/ndt/gfae245. (Online ahead of print).

Article  PubMed  Google Scholar 

Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010;6(8):494–9.

Article  CAS  PubMed  Google Scholar 

Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–89.

Article  PubMed  PubMed Central  Google Scholar 

Nester C, Appel GB, Bomback AS, et al. Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies. Am J Nephrol. 2022;53(10):687–700.

Article  CAS  PubMed  Google Scholar 

Iatropoulos P, Daina E, Curreri M, et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol. 2018;29(1):283–94.

Article  CAS  PubMed  Google Scholar 

Orphanet. Immunoglobulin-mediated membranoproliferative glomerulonephritis. 2021. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=329903. Accessed Oct 9, 2024.

Fukaya D, Inoue T, Kogure Y, et al. Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. CEN Case Rep. 2020;9(4):318–25.

Article  PubMed  PubMed Central  Google Scholar 

Zhang PL, Metcalf BD, Khan S, et al. Hydralazine use can be associated with IgM-dominated immune complex-mediated glomerulonephritis. Ultrastruct Pathol. 2024;48(4):317–22.

Article  CAS  PubMed  Google Scholar 

Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131–42.

Article  CAS  PubMed  Google Scholar 

Nakagawa N, Mizuno M, Kato S, et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: a retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021;16(9):e0257397.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al. Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Kidney Int Rep. 2025. https://doi.org/10.1016/j.ekir.2025.01.024. (Online ahead of print).

Article  Google Scholar 

Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17:7.

Article  PubMed  PubMed Central  Google Scholar 

Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014;9(3):600–8.

Article  PubMed  PubMed Central  Google Scholar 

Garam N, Prohászka Z, Szilágyi Á, et al. Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. Clin Kidney J. 2020;13(2):225–34.

Article  PubMed  Google Scholar 

Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol. 2015;26(11):2852–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh G, Singh SK, Nalwa A, et al. Glomerular C4d staining does not exclude a C3 glomerulopathy. Kidney Int Rep. 2019;4(5):698–709.

Article  PubMed  PubMed Central  Google Scholar 

Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27(5):1278–87.

Article  PubMed  Google Scholar 

Bhandari J, Awais M, Aeddula NR. Cryoglobulinemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

Cruz-Whitley J, Giehl N, Jen KY, Young B. Membranoproliferative glomerulonephritis associated with nivolumab therapy. Case Rep Nephrol. 2020;2020:2638283.

PubMed  PubMed Central  Google Scholar 

Matsuo Y, Mizoguchi F, Kohsaka H, Ito E, Eishi Y, Miyasaka N. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(7):1341–3.

Article  PubMed  Google Scholar 

Wallbach M, Gröne HJ, Kitze B, Müller GA, Koziolek MJ. Nephrotic syndrome in a multiple sclerosis patient receiving long-term interferon beta therapy. Am J Kidney Dis. 2013;61(5):786–9.

Article  CAS  PubMed  Google Scholar 

Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727–34.

Article  PubMed  PubMed Central  Google Scholar 

Shimanovsky A, Alvarez AJ, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12–8.

Article  PubMed  PubMed Central  Google Scholar 

Marinozzi MC, Roumenina LT, Chauvet S, et al. Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN. J Am Soc Nephrol. 2017;28(5):1603–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garam N, Prohászka Z, Szilágyi Á, et al. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Orphanet J Rare Dis. 2019;14(1):247.

Article  PubMed  PubMed Central